Safety and effectiveness of tofacitinib in ulcerative colitis: Data from TOFA-UC, a SN-IBD study-Reference-Cited by-同舟云学术

Safety and effectiveness of tofacitinib in ulcerative colitis: Data from TOFA-UC, a SN-IBD study

Published:2024-01 Issue:1 Volume:56 Page:15-20
ISSN:1590-8658
Container-title:Digestive and Liver Disease
language:en
Short-container-title:Digestive and Liver Disease

Author:

Macaluso Fabio Salvatore^ORCID,D'Antonio Elvira,Fries Walter,Viola Anna,Ksissa Omar,Cappello Maria,Muscarella Stefano,Belluardo Nunzio,Giangreco Emiliano,Mocciaro Filippo,Di Mitri Roberto,Ferracane Concetta,Vitello Alessandro,Grova Mauro,Renna Sara,Casà Angelo,De Vivo Simona,Ventimiglia Marco,Orlando Ambrogio

Funder

Pfizer

Publisher

Elsevier BV

Subject

Gastroenterology,Hepatology

Reference25 articles.

1. The biologics of ulcerative colitis;Macaluso;Expert Opin Biol Ther,2017

2. Expert consensus paper on the use of Vedolizumab for the management of patients with moderate-to-severe Inflammatory Bowel Disease;Armuzzi;Dig Liver Dis,2016

3. Next generation of small molecules in inflammatory bowel disease;Olivera;Gut,2017

4. JAK Inhibition as a therapeutic strategy for inflammatory bowel disease;Macaluso;Curr Drug Metab,2020

5. Ustekinumab as induction and maintenance therapy for ulcerative colitis;Sands;N Engl J Med,2019

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Addressing the safety and efficacy of tofacitinib in ulcerative colitis: A response to the TOFA-UC study;Digestive and Liver Disease;2024-09

2. Remission of refractory esophageal lichen planus induced by tofacitinib;Zeitschrift für Gastroenterologie;2024-06-25

3. Tofacitinib;Reactions Weekly;2024-04-27

4. Implementation of regulatory guidance for JAK inhibitors use in patients with immune-mediated inflammatory diseases: An international appropriateness study;Autoimmunity Reviews;2024-03

5. Tofacitinib in ulcerative colitis – Small molecule but large effect;Digestive and Liver Disease;2024-02